SEC Comment Letter 0000000000-23-005960 to GRI Bio, Inc. (GRI)
GRI Bio, Inc.
Date: June 5, 2023 · CIK: 0001824293 · Accession: 0000000000-23-005960
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272276
Letter
United States securities and exchange commission logo June 5, 2023 Marc Hertz President and CEO GRI BIO, Inc. 2223 Avenida De La Playa, #208 La Jolla, CA 92037 Re:GRI BIO, Inc. Registration Statement on Form S-3 Filed May 30, 2023 File No. 333-272276 Dear Marc Hertz: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Arzhang Navai at 202-551-4676 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jason Miller
Show Raw Text
United States securities and exchange commission logo
June 5, 2023
Marc Hertz
President and CEO
GRI BIO, Inc.
2223 Avenida De La Playa, #208
La Jolla, CA 92037
Re:GRI BIO, Inc.
Registration Statement on Form S-3
Filed May 30, 2023
File No. 333-272276
Dear Marc Hertz:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Arzhang Navai at 202-551-4676 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jason Miller